^
    5d
    Venetoclax-based therapy in high-risk patients with relapsed/refractory multiple myeloma harboring t(11;14): a case report and review of the literature. (PubMed, J Med Case Rep)
    Venetoclax combination regimen achieved excellent efficacy and safety in the treatment of relapsed/refractory multiple myeloma with t(11;14) in this case. The treatment of patients with relapsed and refractory multiple myeloma with t(11;14) by venetoclax still needs to be confirmed by more clinical studies.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Darzalex (daratumumab) • dexamethasone
    6d
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    6d
    Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • sonrotoclax (BGB-11417)
    19d
    AALL2331: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P2/3, N=1708, Not yet recruiting, Children's Oncology Group | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Darzalex (daratumumab) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • nelarabine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Purixan (mercaptopurine oral suspension) • Starasid (cytarabine ocfosfate)
    20d
    A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, HI-Bio, A Biogen Company | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=20 --> 14
    Enrollment closed • Phase classification • Enrollment change
    |
    felzartamab (MOR202)
    20d
    Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Alabama at Birmingham | N=20 --> 40 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment change • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    21d
    Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study (clinicaltrials.gov)
    P2, N=8, Terminated, Mayo Clinic | Trial completion date: Oct 2027 --> Feb 2025 | Active, not recruiting --> Terminated; Slow accrual
    Trial completion date • Trial termination
    |
    Imbruvica (ibrutinib) • Darzalex (daratumumab)
    26d
    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2028 --> Nov 2027
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • JNJ-5322
    28d
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • dexamethasone • dexamethasone injection • isatuximab subcutaneous (SAR650984 SC)
    28d
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=292, Not yet recruiting, Sinocelltech Ltd.
    New P3 trial
    |
    lenalidomide • bortezomib • dexamethasone
    29d
    Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy. (PubMed, Clin Exp Med)
    These findings suggest that t(11;14)-positive AL amyloidosis constitutes a distinct biological and clinical subtype characterized by delayed treatment response to daratumumab. Tailored therapeutic strategies targeting the unique biology of t(11;14)-positive AL amyloidosis is warranted.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab)
    30d
    Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial primary completion date
    |
    carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc)